Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyThiamphenicol
Identification
- Name
- Thiamphenicol
- Accession Number
- DB08621
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Description
- Not Available
- Structure
Structure for Thiamphenicol (DB08621)
- Synonyms
- Not Available
- Categories
- UNII
- FLQ7571NPM
- CAS number
- 15318-45-3
- Weight
- Average: 356.222
Monoisotopic: 355.004798699 - Chemical Formula
- C12H15Cl2NO5S
- InChI Key
- OTVAEFIXJLOWRX-NXEZZACHSA-N
- InChI
- InChI=1S/C12H15Cl2NO5S/c1-21(19,20)8-4-2-7(3-5-8)10(17)9(6-16)15-12(18)11(13)14/h2-5,9-11,16-17H,6H2,1H3,(H,15,18)/t9-,10-/m1/s1
- IUPAC Name
- 2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-methanesulfonylphenyl)propan-2-yl]acetamide
- SMILES
- [H][C@](CO)(NC(=O)C(Cl)Cl)[C@]([H])(O)C1=CC=C(C=C1)S(C)(=O)=O
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
Target Actions Organism UDr hemagglutinin structural subunit Not Available Escherichia coli - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional Data(R)-warfarin The risk or severity of bleeding can be increased when Thiamphenicol is combined with (R)-warfarin. (S)-Warfarin The risk or severity of bleeding can be increased when Thiamphenicol is combined with (S)-Warfarin. 4-hydroxycoumarin The risk or severity of bleeding can be increased when Thiamphenicol is combined with 4-hydroxycoumarin. Acenocoumarol The risk or severity of bleeding can be increased when Thiamphenicol is combined with Acenocoumarol. BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Thiamphenicol. Clorindione The risk or severity of bleeding can be increased when Thiamphenicol is combined with Clorindione. Coumarin The risk or severity of bleeding can be increased when Thiamphenicol is combined with Coumarin. Dicoumarol The risk or severity of bleeding can be increased when Thiamphenicol is combined with Dicoumarol. Diphenadione The risk or severity of bleeding can be increased when Thiamphenicol is combined with Diphenadione. Ethyl biscoumacetate The risk or severity of bleeding can be increased when Thiamphenicol is combined with Ethyl biscoumacetate. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
References
- Synthesis Reference
Franco Pozzi, Claudia Tortora, Angelo Carenzi, "Pharmaceutical preparation containing thiamphenicol for veterinary use." U.S. Patent US4912138, issued January, 1979.
US4912138- General References
- Not Available
- External Links
- KEGG Compound
- C12853
- PubChem Compound
- 27200
- PubChem Substance
- 99445092
- ChemSpider
- 25315
- BindingDB
- 58925
- RxNav
- 10463
- ChEBI
- 32215
- ChEMBL
- CHEMBL1236282
- ZINC
- ZINC000000538440
- PDBe Ligand
- TH8
- Wikipedia
- Thiamphenicol
- ATC Codes
- J01BA02 — Thiamphenicol
- J01BA — Amphenicols
- J01B — AMPHENICOLS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- PDB Entries
- 2jkj
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Basic Science Healthy Volunteers 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.27 mg/mL ALOGPS logP 0.33 ALOGPS logP -0.22 ChemAxon logS -2.2 ALOGPS pKa (Strongest Acidic) 7.65 ChemAxon pKa (Strongest Basic) -2.8 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 103.7 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 79.88 m3·mol-1 ChemAxon Polarizability 32.29 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.931 Blood Brain Barrier + 0.9383 Caco-2 permeable - 0.61 P-glycoprotein substrate Non-substrate 0.7574 P-glycoprotein inhibitor I Non-inhibitor 0.9489 P-glycoprotein inhibitor II Non-inhibitor 0.9432 Renal organic cation transporter Non-inhibitor 0.9236 CYP450 2C9 substrate Non-substrate 0.5856 CYP450 2D6 substrate Non-substrate 0.8164 CYP450 3A4 substrate Non-substrate 0.5896 CYP450 1A2 substrate Non-inhibitor 0.9045 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Non-inhibitor 0.9025 CYP450 3A4 inhibitor Non-inhibitor 0.831 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8529 Ames test Non AMES toxic 0.7181 Carcinogenicity Non-carcinogens 0.6535 Biodegradation Ready biodegradable 0.706 Rat acute toxicity 2.2718 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9972 hERG inhibition (predictor II) Non-inhibitor 0.9289
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-0a4i-0649000000-3f7e62d09a29a445c8a6 MS/MS Spectrum - , positive LC-MS/MS splash10-0002-2931000000-1f1691e17ae627c7d762
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as benzenesulfonyl compounds. These are aromatic compounds containing a benzenesulfonyl group, which consists of a monocyclic benzene moiety that carries a sulfonyl group.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzenesulfonyl compounds
- Direct Parent
- Benzenesulfonyl compounds
- Alternative Parents
- Sulfones / Secondary carboxylic acid amides / Secondary alcohols / Primary alcohols / Organopnictogen compounds / Organonitrogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds show 2 more
- Substituents
- Benzenesulfonyl group / Sulfone / Sulfonyl / Carboxamide group / Secondary alcohol / Secondary carboxylic acid amide / Carboxylic acid derivative / Alcohol / Aromatic alcohol / Hydrocarbon derivative show 14 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- sulfone, monocarboxylic acid amide (CHEBI:32215)
Targets
- Kind
- Protein
- Organism
- Escherichia coli
- Pharmacological action
- Unknown
- General Function
- Not Available
- Specific Function
- Hemagglutinins of uropathogenic E.coli mediate adherence to the upper urinary tract. These adhesins bind to the Dr blood group antigen and also agglutinate human erythrocytes in the presence of D-m...
- Gene Name
- draA
- Uniprot ID
- P24093
- Uniprot Name
- Dr hemagglutinin structural subunit
- Molecular Weight
- 17058.095 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Drug created on September 15, 2010 15:33 / Updated on March 01, 2020 20:21
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates